초록 ▼

This invention provides populations human cells of the cardiomyocyte lineage. The cells are obtained by causing cultures of pluripotent stem cells to differentiate in vitro, and then harvesting cells with certain phenotypic features. Differentiated cells bear cell surface and morphologic markers cha

This invention provides populations human cells of the cardiomyocyte lineage. The cells are obtained by causing cultures of pluripotent stem cells to differentiate in vitro, and then harvesting cells with certain phenotypic features. Differentiated cells bear cell surface and morphologic markers characteristic of cardiomyocytes, and a proportion of them undergo spontaneous periodic contraction. Highly enriched populations of cardiomyocytes and their replicating precursors can be obtained, suitable for use in a variety of applications, such as drug screening and therapy for cardiac disease.

대표청구항 ▼

The invention claimed is: 1. A method of screening a compound for an effect on a cardiomyocyte in cell culture, comprising: a) contacting the cell culture with the compound; and b) observing a change in a cardiomyocyte in the cell culture compared to a cardiomyocyte in an untreated cell culture and

The invention claimed is: 1. A method of screening a compound for an effect on a cardiomyocyte in cell culture, comprising: a) contacting the cell culture with the compound; and b) observing a change in a cardiomyocyte in the cell culture compared to a cardiomyocyte in an untreated cell culture and c) determining a difference between the treated and untreated cardiomyocyte in the respective cell cultures, wherein the cell culture comprises 5% or more cardiomyocytes that are at least 99.6% genetically identical to an established line of non-malignant cells which express SSEA3, SSEA4, Tra-1-60 and Tra-1-81. 2. The method of claim 1, wherein the compound is a drug. 3. The method of claim 2, wherein the drug is calcium channel blocker. 4. The method of claim 2, wherein the drug is a β-adrenoreceptor agonist. 5. The method of claim 2, wherein the drug is an α-adrenoreceptor agonist. 6. The method of claim 1, wherein the compound is a peptide. 7. The method of claim 1, wherein the compound is an oligonucleotide. 8. The method of claim 1, wherein the compound is a cytotoxin. 9. The method of claim 1, wherein the cell culture comprises 5% or more cardiomyocytes that are 99.7% genetically identical to an established line of non-malignant cells which express SSEA3, SSEA4, Tra-1-60 and Tra-1-81. 10. The method of claim 1, wherein the cell culture comprises 5% or more cardiomyocytes that are 99.8% genetically identical to an established line of non-malignant cells which express SSEA3, SSEA4, Tra-1-60 and Tra-1-81.38. 11. The method of claim 1, wherein the cell culture comprises 5% or more cardiomyocytes that are 99.9% genetically identical to an established line of non-malignant cells which express SSEA3, SSEA4, Tra-1-60 and Tra-1-81.38. 12. The method of claim 1, wherein the cell culture comprises 5% or more cardiomyocytes that have the same genome as an established line of non-malignant cells which express SSEA3, SSEA4, Tra-1-60 and Tra-1-81. 13. A method of screening a compound for an effect on a cell in cell culture, comprising: a) contacting the cell culture with a compound; and b) observing a change in a myosin heavy chain expressing cell in the cell culture compared to a myosin heavy chain expressing cell in an untreated cell culture and c) determining a difference between the treated and untreated myosin heavy chain expressing cell in the respective cell cultures, wherein the cell culture comprises 5% or more cells that express myosin heavy chain and are at least 99.6% genetically identical to an established line of non-malignant cells which express SSEA3, SSEA4, Tra-1-60 and Tra-1-81. 14. The method of claim 13 wherein the compound is a drug. 15. The method of claim 14, wherein the drug is calcium channel blocker. 16. The method of claim 14, wherein the drug is a β-adrenoreceptor agonist. 17. The method of claim 14, wherein the drug is an α-adrenoreceptor agonist. 18. The method of claim 13, wherein the compound is a peptide. 19. The method of claim 13, wherein the compound is an oligonucleotide. 20. The method of claim 13, wherein the compound is a cytotoxin. 21. The method of claim 13, wherein the cell culture comprises 5% or more cardiomyocytes that are 99.7% genetically identical to an established line of non-malignant cells which express SSEA3, SSEA4, Tra-1-60 and Tra-1-81. 22. The method of claim 13 wherein the cell culture comprises 5% or more cardiomyocytes that are 99.8% identical to an established line of non-malignant cells which express SSEA3, SSEA4, Tra-1-60 and Tra-1-81. 23. The method of claim 13, wherein the cell culture comprises 5% or more cardiomyocytes that are 99.9% genetically identical to an established line of non-malignant cells which express SSEA3, SSEA4, Tra-1-60 and Tra-1-81. 24. The method of claim 13, wherein the cell culture comprises 5% or more cardiomyocytes that have the same genome as an established line of non-malignant cells which express SSEA3, SSEA4, Tra-1-60 and Tra-1-81.